Investors/Media

Shareholder Tools

Press Releases

Date	Title and Summary	View
Toggle SummarySep 18, 2006	Acceleron Pharma Presents ACE-011 Preclinical Data Demonstrating Both Anabolic and Anti-Resorptive Properties Novel Approach Represents Significant Advance for the Treatment of Bone Loss	View HTML Acceleron Pharma Presents ACE-011 Preclinical Data Demonstrating Both Anabolic and Anti-Resorptive Properties 13.9 KB
Toggle SummarySep 12, 2006	Acceleron Pharma to Present ACE-011 Preclinical Data at the Annual Meeting of the American Society for Bone and Mineral Research Preclinical Data Demonstrate Dual Activity of ACE-011	View HTML Acceleron Pharma to Present ACE-011 Preclinical Data at the Annual Meeting of the American Society for Bone and Mineral Research 11.5 KB
Toggle SummaryAug 21, 2006	Red Herring: Growing a Backbone; VC’s Finance Bone Loss Treatment Red Herring: Growing a Backbone; VC’s Finance Bone Loss Treatment Red Herring, August 21, 2006	View HTML Red Herring: Growing a Backbone; VC’s Finance Bone Loss Treatment 8 KB
Toggle SummaryAug 03, 2006	BioWorld Today: Acceleron Secures $30M in Series B BioWorld Today: Acceleron Secures $30M in Series B BioWorld Today, August 3, 2006	View HTML PDF Version
Toggle SummaryAug 02, 2006	Acceleron Pharma Closes $30M Series B Financing Acceleron Pharma Closes $30M Series B Financing CAMBRIDGE, MA – August 2, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, today announced that it secured a $30 million Series B financing.	View HTML Acceleron Pharma Closes $30M Series B Financing 11.9 KB
Toggle SummaryJul 17, 2006	BioCentury: Acceleron: Value in the Wallflower BioCentury: Acceleron: Value in the Wallflower BioCentury, July 17, 2006	View HTML PDF Version
Toggle SummaryJun 21, 2006	Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss Acceleron Becomes a Clinical-Stage Company	View HTML Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss 14.1 KB
Toggle SummaryMay 16, 2006	Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer Dr. Sherman’s Expertise in Building a Clinical Development Organization and Advancing Programs Through Regulatory Approval a Key Addition to the Management Team	View HTML Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer 11.8 KB
Toggle SummaryJun 14, 2004	Acceleron Pharma Appoints Glenn Batchelder as CEO and Adds Richard F. Pops to Board of Directors Acceleron Pharma Appoints Glenn Batchelder as CEO and Adds Richard F. Pops to Board of Directors CAMBRIDGE, MA – June 14, 2004 – Acceleron Pharma announced today the appointment of Glenn Batchelder as president and CEO and a member of the board of directors.	View HTML Acceleron Pharma Appoints Glenn Batchelder as CEO and Adds Richard F. Pops to Board of Directors 11.5 KB
Toggle SummaryFeb 13, 2004	Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding BOSTON, MA – February 13, 2004 – Acceleron Pharma, a biopharmaceutical company developing drugs to treat musculoskeletal and metabolic disorders, announced today that it has	View HTML Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding 10.1 KB